Radioimmunotherapy (RIT)

  • F. F. (Russ) Knapp
  • Ashutosh Dash


Immunotherapy is a therapeutic modality that utilizes the antibody–antigen mechanism to enhance or suppress the immune response for management of a range of disorders (Baxevanis et al., Crit Rev Clin Lab Sci 46(4):167–189, 2009; King et al., QJM 101(9):675–683, 2008; Krüger et al., Histol Histopathol 22(6):687–669, 2007; Matzku and Zöller, Drugs Aging 18(9):639–664, 2001). Antibodies are glycoproteins produced by lymphocytes to combat infection and foreign organisms utilizing a system that has evolved over millions of years to protect animals from environment insults (Scott et al., Nature Rev Cancer 12:278–287, 2012). As part of the immune regulatory system, antibodies are also widely used as vaccines for treating or preventing infections as one of the most important disease control tools in medicine. Antibodies are also are being developed for use against other diseases, including cancers and virus-based diseases. In this chapter, the biology and function of antibodies and antigens are first described in detail, as a basis for the introduction of the development and use of radioimmunotherapy (RIT), where therapeutic radioisotopes are attached to targeting antigens as a unique strategy to deliver ionizing radiation to the target site. The basics of some key clinical disorders such as lymphomas are also described, since their treatment with radiolabeled antibodies represents a spectacular success in this field.


Antigenic Determinant Antibody Molecule Multiple Epitope Therapeutic Radionuclide Lymphoreticular Malignancy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Ahlskog J, Paganelli G, Neri D. Vascular tumor targeting. Q J Nucl Med Mol Imaging. 2006;50:296–309.PubMedGoogle Scholar
  2. Anand P, Kunnumakara AB, Sundaram C. Cancer is a preventable disease that requires major lifestyle changes. Pharm Res. 2008;25(9):2097–116.PubMedPubMedCentralCrossRefGoogle Scholar
  3. Azinovic I, DeNardo GL, Lamborn KR, et al. Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies. Cancer Immunol Immunother. 2006;55:1451–8.PubMedCrossRefGoogle Scholar
  4. Barendswaard EC, Humm JL, O’Donoghue JA. Therapeutic efficacy of 125I- and 131I-labeled monoclonal antibody A33 in a human colon cancer xenograft. J Nucl Med. 2001;42:1251–6.PubMedGoogle Scholar
  5. Baxevanis CN, Perez SA, Papamichail M. Cancer immunotherapy. Crit Rev Clin Lab Sci. 2009;46(4):167–89.PubMedCrossRefGoogle Scholar
  6. Behr TM, Sgouros G, Vougiokas V, et al. Therapeutic efficacy and dose limiting toxicity of Auger-electron versus beta emitters in radioimmunotherapy with internalizing antibodies: evaluation of 125I-versus 131I-labeled CO17-1A in a human colorectal cancer model. Int J Cancer. 1998;76:738–48.PubMedCrossRefGoogle Scholar
  7. Berenson A. Market forces cited in lymphoma drugs’ Disuse. New York Times, 14 Jul 2007.Google Scholar
  8. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9:653–60.PubMedCrossRefGoogle Scholar
  9. Caron PC, Schwartz MA, Co MS. Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia. Cancer. 1994;73:1049–56.PubMedCrossRefGoogle Scholar
  10. Chatal JF, Mahé M. Therapeutic use of radiolabelled antibodies. In: Murray IPC, Ell PJ, editors. Nuclear medicine in clinical diagnosis and treatment. Edinburgh: Churchill Livingstone; 1998. p. 1101–14.Google Scholar
  11. Dillman RD. Monoclonal antibody therapy. In: Oldman RK, editor. Principles of cancer biotherapy. 4th ed. Norwell: Kluwer Academic Publishers; 2003. p. 329–90.CrossRefGoogle Scholar
  12. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27–31.PubMedCrossRefGoogle Scholar
  13. Goldenberg DM. The role of radiolabeled antibodies in the treatment of non-Hodgkin’s lymphoma: the coming of age of radioimmunotherapy. Crit Rev Oncol Hematol. 2001;39:195–201.PubMedCrossRefGoogle Scholar
  14. Goldenberg DM, Sharkey RM. Advances in cancer therapy with radiolabeled monoclonal antibodies. Q J Nucl Med Mol Imaging. 2006;50:248–64.PubMedGoogle Scholar
  15. Goldenberg DM, Gaffar SA, Bennett SJ, et al. Experimental radioimmunotherapy of a xenografted human colonic tumor (GW-39) producing carcinoembryonic antigen. Cancer Res. 1981;41:4354–60.PubMedGoogle Scholar
  16. Goldsmith SJ. Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Semin Nucl Med. 2010;40:122–35.PubMedCrossRefGoogle Scholar
  17. Griffiths GL, Govindan SV, Sgouros G, et al. Cytotoxicity with auger electron- emitting radionuclides delivered by antibodies. Int J Cancer. 1999;81:985–92.PubMedCrossRefGoogle Scholar
  18. Humm JL. A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy. Int J Radiat Oncol Biol Phys. 1987;13:1767–73.PubMedCrossRefGoogle Scholar
  19. Humm JL. Problems and advances in the dosimetry of radionuclide targeted therapy. In: Bihl S, Luise M, Bihl H, Wannenmacher M, editors. Systemic radiotherapy with monoclonal antibodies, options and problems. Berlin/Heidelberg/Germany: Springer; 1996. p. 37–66.CrossRefGoogle Scholar
  20. Kaminski MS, Zasadny KR, Francis IR, et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med. 1993;329:459–65.PubMedCrossRefGoogle Scholar
  21. Kawashima H. Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies. Scientific World Journal. 2014;49:2061.Google Scholar
  22. King J, Waxman J, Stauss H. Advances in tumour immunotherapy. QJM. 2008;101(9):675–83.PubMedCrossRefGoogle Scholar
  23. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–7.PubMedCrossRefGoogle Scholar
  24. Kozak RW, Atcher RW, Gansow OA. Bismuth-212-labeled anti-TAC monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy. Proc Natl Acad Sci. 1986;83:474–8.PubMedPubMedCentralCrossRefGoogle Scholar
  25. Krüger C, Greten TF, Korangy F. Immune based therapies in cancer. Histol Histopathol. 2007;22(6):687–96.PubMedGoogle Scholar
  26. Küppers R. Molecular biology of Hodgkin’s lymphoma. Adv Cancer Res. 2002;44:277–312.CrossRefGoogle Scholar
  27. Matzku S, Zöller M. Specific immunotherapy of cancer in elderly patients. Drugs Aging. 2001;18(9):639–64.PubMedCrossRefGoogle Scholar
  28. Michel RB, Andrews PM, Rosario AV, et al. 177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo. Nucl Med Biol. 2005;32:269–78.PubMedCrossRefGoogle Scholar
  29. Müschen M, Rajewsky K, Bräuninger A, et al. Rare occurrence of classical Hodgkin’s disease as a T cell lymphoma. J Exp Med. 2000;191:387–94.PubMedPubMedCentralCrossRefGoogle Scholar
  30. Postema EJ, Boerman OC, Oyen WJ, et al. Radioimmunotherapy of B-cell non-Hodgkin’s lymphoma. Eur J Nucl Med. 2001;28:1725–35.PubMedCrossRefGoogle Scholar
  31. Sautter-Bihl ML, Herbold G, Bihl H. Minimal residual disease: a target for radioimmunotherapy with 131I-labeled monoclonal antibodies? Some dosimetric considerations. Recent Results Cancer Res. 1996;141:67–75.PubMedCrossRefGoogle Scholar
  32. Schlom J, Colcher D, Siler K, et al. Tumor targeting with monoclonal antibody B72.3: experimental and clinical results. Cancer Treat Res. 1990;51:313–35.PubMedCrossRefGoogle Scholar
  33. Schroff RW, Foon KA, Beatty SM, et al. Human antimurine immunoglobulin responses in patients receiving MoAb therapy. Cancer Res. 1985;45:879–85.PubMedGoogle Scholar
  34. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12:278–87.PubMedCrossRefGoogle Scholar
  35. Seitz V, Hummel M, Marafioti T, et al. Detection of clonal T-cell receptor gamma-chain gene rearrangements in Reed-Sternberg cells of classic Hodgkin disease. Blood. 2000;95:3020–4.PubMedGoogle Scholar
  36. Sharkey RM, Brenner A, Burton J, et al. Radioimmunotherapy of non-Hodgkin’s lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med. 2003;44:2000–18.PubMedGoogle Scholar
  37. Tosato G, Magrath IT, Koski IR, et al. B cell differentiation and immunoregulatory T cell function in human cord blood lymphocytes. J Clin Invest. 1980;66(2):383–8.PubMedPubMedCentralCrossRefGoogle Scholar
  38. Trikha M, Yan L, Nakada MT. Monoclonal antibodies as therapeutics in oncology. Curr Opin Biotechnol. 2002;13:609–14.PubMedCrossRefGoogle Scholar
  39. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010;10:317–27.PubMedPubMedCentralCrossRefGoogle Scholar
  40. Weiss LM, Chan JKC, MacLennan K, et al. Pathology of classical Hodgkin’s disease. In: Mauch PM, Armitage JO, Diehl V, Hoppe RT, Weiss LM, editors. Hodgkin’s disease. Philadelphia: Lippincott Williams & Wilkins; 1999. p. 101–20.Google Scholar
  41. White CA, Berlfein JR, Grillo-Lopez AJ. Antibody-targeted immunotherapy for treatment of non-Hodgkin’s lymphoma. Curr Pharm Biotechnol. 2000;1:303–12.PubMedCrossRefGoogle Scholar
  42. Winter G, Harris WJ. Humanized antibodies. Trends Pharmacol Sci. 1993;14:139–43.PubMedCrossRefGoogle Scholar
  43. Wiseman GA, White CA, Sparks RB. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. Crit Rev Oncol Hematol. 2001;39:181–94.PubMedCrossRefGoogle Scholar
  44. Witzig TE. Radioimmunotherapy for patients with relapsed B-cell non- Hodgkin lymphoma. Cancer Chemother Pharmacol. 2001;48:91S–5.CrossRefGoogle Scholar
  45. Zalutsky MR, Schuster JM, Garg PK, et al. Two approaches for enhancing radioimmunotherapy: a emitters and hyperthermia. In: Bihl SML, Bihl H, Wannenmacher M, editors. Systemic radiotherapy with monoclonal antibodies, options and problems. Berlin/Heidelberg/Germany: Springer; 1996. p. 101–22.CrossRefGoogle Scholar
  46. Zola H, Swart B. The human leucocyte differentiation antigens (HLDA) workshops: the evolving role of antibodies in research, diagnosis and therapy. Cell Res. 2005;15:691–4.PubMedCrossRefGoogle Scholar
  47. Zola H, Swart B, Nicholson I, et al. CD molecules 2005: human cell differentiation molecules. Blood. 2005;106(9):3123–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer India 2016

Authors and Affiliations

  • F. F. (Russ) Knapp
    • 1
  • Ashutosh Dash
    • 2
  1. 1.Nuclear Security and Isotope DivisionOak Ridge National LaboratoryOAK RIDGEUSA
  2. 2.Isotope Production and Applications DivisionBhabha Atomic Research CentreMumbaiIndia

Personalised recommendations